EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer

Manoj Amrutkar iD, Sander Johannes Thorbjørnsen Guttorm, Anette Vefferstad Finstadsveen, Knut Jørgen Labori, Lars Eide, Helge Rootwelt, Katja Benedikte Prestø Elgstøen, Ivar P Gladhaug, Caroline S Verbeke

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Manoj Amrutkar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Norway. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Metabolomics, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kreftforeningen, Helse Sør-Øst RHF, University of Oslo, Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant chemotherapy (NAT) is increasingly used for the treatment of non‐metastatic pancreatic ductal adenocarcinoma (PDAC) and is established as a standard of care for borderline resectable and locally advanced PDAC. However, full exploitation of its clinical benefits is limited by the lack of biomarkers that assess treatment response. To address this unmet need, global metabolomic profiling was performed on tumor tissue and paired serum samples from patients with treatment‐naïve (TN; n = 18) and neoadjuvant leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX)‐treated (NAT; n = 17) PDAC using liquid chromatography mass spectrometry. Differentially abundant metabolites (DAMs) in TN versus NAT groups were identified and their correlation with various clinical parameters was assessed. Metabolomics profiling identified 40 tissue and five serum DAMs in TN versus NAT PDAC. In general, DAMs associated with amino acid and nucleotide metabolism were lower in NAT compared to TN. Four DAMs—3‐hydroxybutyric acid (BHB), 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF), glycochenodeoxycholate and citrulline—were common to both tissue and serum and showed a similar pattern of differential abundance in both groups. A strong positive correlation was observed between serum carbohydrate 19‐9 antigen (CA 19‐9) and tissue carnitines (C12, C18, C18:2) and N8‐acetylspermidine. The reduction in CA 19‐9 following NAT correlated negatively with serum deoxycholate levels, and the latter correlated positively with survival. This study revealed neoadjuvant‐chemotherapy‐induced changes in metabolic pathways in PDAC, mainly amino acid and nucleotide metabolism, and these correlated with reduced CA 19‐9 following neoadjuvant FOLFIRINOX treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoadjuvant TherapyMetabolomicsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Pancreatic DuctalMetabolomeHumansLeucovorinFluorouracilFemaleMaleIrinotecanOxaliplatinMiddle AgedAgedAdult

Stichwörter der Autor:innen

FOLFIRINOXLC–MSneoadjuvant chemotherapypancreatic canceruntargeted metabolomics

Substanzen

LeucovorinFluorouracilIrinotecanOxaliplatinfolfirinoxBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Norway.
  • Department of Medical Biochemistry, Division of Laboratory Medicine, Oslo University Hospital, Norway.
  • Core Facility for Global Metabolomics and Lipidomics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
  • Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
  • Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway.
  • Department of Medical Biochemistry, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.

ORCID-Profile: Manoj Amrutkar

Förderung

  • Kreftforeningen
  • Helse Sør-Øst RHF
  • University of Oslo, Norway

Zitieren

APA

Amrutkar, M., Guttorm, S. J. T., Finstadsveen, A. V., Labori, K. J., Eide, L., Rootwelt, H., Elgstøen, K. B. P., Gladhaug, I. P., & Verbeke, C. S. (2025). Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.13759

Vancouver

Amrutkar M, Guttorm SJT, Finstadsveen AV, Labori KJ, Eide L, Rootwelt H, et al. Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer. Molecular Oncology. 2025. doi:10.1002/1878-0261.13759

BibTeX
@article{Amrutkar2025,
  author = {Amrutkar, Manoj and Guttorm, Sander Johannes Thorbjørnsen and Finstadsveen, Anette Vefferstad and Labori, Knut Jørgen and Eide, Lars and Rootwelt, Helge and Elgstøen, Katja Benedikte Prestø and Gladhaug, Ivar P and Verbeke, Caroline S},
  title = {Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13759}
}
Kostenlos starten →